Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ahr-10282
2. Bromfenac
3. Duract
4. Isv-303
5. Sodium Bromfenac
6. Xibrom
1. 91714-93-1
2. 120638-55-3
3. Bromfenac (sodium)
4. Bronuck
5. Bromfenac Sodium Salt
6. Bromsite
7. Bromfenac Sodium Anhydrous
8. Xibrom
9. Chebi:140536
10. Ahr 10282b
11. Bromfenac Monosodium Salt Sesquihydrate
12. Bromfenac (sodium Hydrate)
13. Benzeneacetic Acid, 2-amino-3-(4-bromobenzoyl)-, Monosodium Salt
14. Sodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate
15. 9x8yf771ou
16. Bromday
17. Prolensa
18. Sodium 2-(2-amino-3-(4-bromobenzoyl)phenyl)acetate
19. Ahr-10282b
20. Bromfenac Sodium Hydrate
21. Sodium 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate
22. 2-amino-3-(4-bromobenzoyl)benzeneacetic Acid Sodium Salt
23. Bromfenac Sodium Salt Sesquihydrate
24. Unii-9x8yf771ou
25. Sodium [2-amino-3-(4-bromobenzoyl)phenyl]acetate
26. Mfcd03701673
27. Benzeneacetic Acid, 2-amino-3-(4-bromobenzoyl)-, Sodium Salt (1:1)
28. Bromfenac Monosodium Salt
29. Chembl751
30. Schembl56644
31. Hy-b1888a
32. Dtxsid70273981
33. Bromfenac Sodium [who-dd]
34. Ahr 10282r
35. Hms3652d21
36. Hms3885l13
37. Amy22137
38. Bcp05811
39. Bromfenac Sodium, >=98% (hplc)
40. Ac-149
41. Bdbm50225143
42. S4248
43. Akos000280377
44. Bromfenac Monosodium Salt [mi]
45. Ac-9334
46. Ccg-268104
47. Sb17363
48. Bb164264
49. Cs-0014295
50. Ft-0602701
51. Ft-0660252
52. Sw219148-1
53. Sodium 2-amino-3-(4-bromobenzoyl) Phenylacetate
54. J-004372
55. Q-200752
56. Sodium2-(2-amino-3-(4-bromobenzoyl)phenyl)acetate
57. Q27225685
58. Sodium (-amino-3-(p-bromobenzoyl)phenyl)acetate
59. Sodium; [2-amino-3-(4-bromo-benzoyl)-phenyl]-acetate
60. Benzeneacetic Acid,2-amino-3-(4-bromobenzoyl)-,monosodium Salt
61. Ahr 10282b;ahr-10282; Ahr10282; Ahr 10282;sodium Bromfenac
Molecular Weight | 356.15 g/mol |
---|---|
Molecular Formula | C15H11BrNNaO3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 354.98200 g/mol |
Monoisotopic Mass | 354.98200 g/mol |
Topological Polar Surface Area | 83.2 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 372 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Bromfenac sodium |
Drug Label | Bromfenac ophthalmic solution 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of bromfenac ophthalmic solution contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfen... |
Active Ingredient | Bromfenac sodium |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.09% acid |
Market Status | Prescription |
Company | Apotex; Hi-tech Pharmacal; Luitpold; Coastal Pharms |
2 of 2 | |
---|---|
Drug Name | Bromfenac sodium |
Drug Label | Bromfenac ophthalmic solution 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of bromfenac ophthalmic solution contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfen... |
Active Ingredient | Bromfenac sodium |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.09% acid |
Market Status | Prescription |
Company | Apotex; Hi-tech Pharmacal; Luitpold; Coastal Pharms |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
31
PharmaCompass offers a list of Bromfenac Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bromfenac Sodium manufacturer or Bromfenac Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bromfenac Sodium manufacturer or Bromfenac Sodium supplier.
PharmaCompass also assists you with knowing the Bromfenac Sodium API Price utilized in the formulation of products. Bromfenac Sodium API Price is not always fixed or binding as the Bromfenac Sodium Price is obtained through a variety of data sources. The Bromfenac Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Bromfenac Sodium Sesquihydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bromfenac Sodium Sesquihydrate, including repackagers and relabelers. The FDA regulates Bromfenac Sodium Sesquihydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bromfenac Sodium Sesquihydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bromfenac Sodium Sesquihydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Bromfenac Sodium Sesquihydrate supplier is an individual or a company that provides Bromfenac Sodium Sesquihydrate active pharmaceutical ingredient (API) or Bromfenac Sodium Sesquihydrate finished formulations upon request. The Bromfenac Sodium Sesquihydrate suppliers may include Bromfenac Sodium Sesquihydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Bromfenac Sodium Sesquihydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Bromfenac Sodium Sesquihydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Bromfenac Sodium Sesquihydrate active pharmaceutical ingredient (API) in detail. Different forms of Bromfenac Sodium Sesquihydrate DMFs exist exist since differing nations have different regulations, such as Bromfenac Sodium Sesquihydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bromfenac Sodium Sesquihydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Bromfenac Sodium Sesquihydrate USDMF includes data on Bromfenac Sodium Sesquihydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bromfenac Sodium Sesquihydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bromfenac Sodium Sesquihydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Bromfenac Sodium Sesquihydrate Drug Master File in Japan (Bromfenac Sodium Sesquihydrate JDMF) empowers Bromfenac Sodium Sesquihydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Bromfenac Sodium Sesquihydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Bromfenac Sodium Sesquihydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Bromfenac Sodium Sesquihydrate suppliers with JDMF on PharmaCompass.
A Bromfenac Sodium Sesquihydrate written confirmation (Bromfenac Sodium Sesquihydrate WC) is an official document issued by a regulatory agency to a Bromfenac Sodium Sesquihydrate manufacturer, verifying that the manufacturing facility of a Bromfenac Sodium Sesquihydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bromfenac Sodium Sesquihydrate APIs or Bromfenac Sodium Sesquihydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Bromfenac Sodium Sesquihydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Bromfenac Sodium Sesquihydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bromfenac Sodium Sesquihydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bromfenac Sodium Sesquihydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bromfenac Sodium Sesquihydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bromfenac Sodium Sesquihydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bromfenac Sodium Sesquihydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bromfenac Sodium Sesquihydrate suppliers with NDC on PharmaCompass.
Bromfenac Sodium Sesquihydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bromfenac Sodium Sesquihydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bromfenac Sodium Sesquihydrate GMP manufacturer or Bromfenac Sodium Sesquihydrate GMP API supplier for your needs.
A Bromfenac Sodium Sesquihydrate CoA (Certificate of Analysis) is a formal document that attests to Bromfenac Sodium Sesquihydrate's compliance with Bromfenac Sodium Sesquihydrate specifications and serves as a tool for batch-level quality control.
Bromfenac Sodium Sesquihydrate CoA mostly includes findings from lab analyses of a specific batch. For each Bromfenac Sodium Sesquihydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bromfenac Sodium Sesquihydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Bromfenac Sodium Sesquihydrate EP), Bromfenac Sodium Sesquihydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bromfenac Sodium Sesquihydrate USP).